Gujarat to Global: Empowering MedTech Ecosystem to be held in Gandhinagar on June 23
Gandhinagar, June 20
Gujarat Rajya Institution for Transformation and Export Promotion Council for Medical Devices, will jointly host a high-impact MedTech sector conference titled 'Gujarat to Global: Empowering the MedTech Ecosystem' on Tuesday in Gandhinagar.
The conference comes at a crucial juncture for Gujarat's medical device sector. With the Nagalpar Medical Device Park near Rajkot now operational, manufacturers in the state are increasingly moving beyond basic assembly towards advanced, export-oriented manufacturing.
The event aims to bridge the gap between local manufacturing capabilities and global market opportunities by bringing together policymakers, regulators, and industry leaders on a common platform.
The conference will commence with a session on policy and industry perspectives, setting the context through "The 2030 Roadmap: Gujarat's Role in India's USD 30 Billion MedTech Vision." This will be followed by an interactive discussion on the pulse of Gujarat's MedTech manufacturing sector, focusing on key policy, regulatory, and market access challenges.
Senior government officials, including representatives from the Department of Pharmaceuticals, Department of Commerce, and CDSCO, will participate in the deliberations alongside industry leaders from leading companies such as SMT, BPL, Meril Life Sciences, and Philips India.
A dedicated technical session will provide a strategic framework for global regulatory submissions, covering key FDA pathways, 510(k), De Novo, and PMA, and their alignment with the European Union's MDR and IVDR requirements. Experts from CDSCO, FDA third-party review bodies, and EU notified bodies will share insights on navigating international regulatory frameworks.
The session will be followed by discussions on building export-ready quality systems for global market access. Deliberations will focus on aligning ZED parameters with international quality standards and leveraging Free Trade Agreements (FTAs) to enhance export competitiveness. Experts from Invest India, ADMI, Panacea Medical Technologies, Wipro GE Healthcare, and other leading organisations.
The concluding session will focus on strengthening the ecosystem supporting Gujarat's Medical Device Park. Discussions will centre on key enablers, including infrastructure development, regulatory facilitation, research and innovation, supply chain localisation, skill development, and industry-academia collaboration.
The conference will be chaired by S Aparna (Retd. IAS), Chief Executive Officer, GRIT. Senior officials from the Department of Pharmaceuticals and the Department of Commerce, Government of India, will participate in the event, which is expected to bring together more than two dozen industry and government stakeholders across various sessions.
— ANI
Reader Comments
Good to see focus on regulatory pathways like FDA 510(k) and EU MDR. Indian companies often struggle with international compliance. This could be a real boost for smaller manufacturers who want to export but don't know where to start. Hope they also address the high cost of certification.
The USD 30 billion MedTech vision by 2030 is ambitious but achievable if we improve R&D and supply chain localisation. Too often we import even basic components. Glad to see Philips India and Wipro GE Healthcare involved - they can share best practices from global markets.
Interesting to see an American company like BPL involved - shows the global interest in India's MedTech growth. But I hope the conference also discusses affordability for Indian patients, not just exports. We need Make in India to benefit our own healthcare system first.
Finally, a conference that brings together policymakers AND industry leaders. The inclusion of CDSCO, Invest India, and ADMI is crucial. One suggestion: please also invite representatives from smaller MSMEs who make up the backbone of Gujarat's manufacturing sector.
As someone working in a medical device startup, I'm excited but also cautious. The regulatory sessions on FDA and EU MDR are much needed, but we need simpler processes for domestic approval too. 80% of our sales are still in India. Let's not forget the home market while chasing global dreams.
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.